TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The CDC’s updated 2026 antimicrobial-resistance report identifies 19 pathogens at threat levels ranging from concerning to urgent, plus six on a watch list. The agency estimates the pathogens collectively cause 9.7 million infections and 50,800 deaths annually in the United States; the total is not limited to the four drug-resistant organisms classified as urgent.
The CDC’s updated 2026 Antimicrobial Resistance Threats Report identifies 19 pathogens with threat levels ranging from concerning to urgent and estimates that the organisms collectively cause 9.7 million infections and 50,800 deaths each year in the United States. Four drug-resistant pathogens sit in the agency’s top urgent category, while six additional organisms are on a watch list.
The four pathogens named as urgent drug-resistant threats are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae. The CDC’s report describes the organisms as public-health threats requiring aggressive action. The headline figure of 50,800 deaths refers to the pathogens covered by the report collectively, not just these four urgent threats.
The report also records changes in classification. Clostridioides difficile moved from urgent to serious, with the CDC citing successful infection-prevention measures that have helped reduce cases since 2011. Drug-resistant N. meningitidis was added to the serious category. Drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria are among the additions to the six-organism watch list, which tracks potential threats whose disease burden remains uncertain.
The report gives examples of the burden behind its assessments. In 2023, carbapenem-resistant Acinetobacter was linked to an estimated 817 U.S. deaths and 9,497 hospitalizations; carbapenem-resistant Enterobacterales to an estimated 1,252 deaths and 14,878 hospitalizations. The CDC also reports that U.S. C. auris cases rose from 48 in 2016 to 4,523 in 2023. These are organism-specific figures for the stated year, not annual averages for all pathogens.
Risks for Patients and Hospitals
Antimicrobial resistance can make infections harder to treat when medicines that once worked are less effective. The report’s concerns extend beyond infection outcomes: drug-resistant infections can complicate treatment for people already receiving care for serious illnesses and can add pressure to hospitals and other health services.
Wendy Armstrong, president of the Infectious Diseases Society of America, said in a statement that these infections can prolong hospital stays and raise health-care costs. She also warned they can make it more difficult for clinicians to provide care such as chemotherapy, organ transplants and joint replacements safely. Those are her comments on the report’s implications, rather than a separate CDC estimate of how many procedures are affected.
The threat categories also help distinguish immediate concerns from organisms the agency is monitoring. A watch-list designation signals a potential risk, not proof that an organism is already causing a large or increasing burden nationwide. The report’s data can inform public-health priorities, infection prevention and decisions about developing new treatments.
Products Worth Considering
Theragun Relief Massage Gun, 3-Speed, Black
Therabody JetBoots Prime Wireless Compression Boots – Short (under 29 inseam)
Oura Ring 4 Smart Ring – Silver – Size 8
As an affiliate, we earn on qualifying purchases.
How the CDC Ranks Pathogens
The CDC’s 2026 report updates its assessment of antimicrobial-resistance threats in the United States. It groups pathogens across categories described as concerning, serious and urgent, and separately identifies organisms on a watch list. The classifications reflect the agency’s assessment of public-health threats; they do not mean each listed organism poses the same level of risk to every person or setting.
Among the urgent threats, carbapenem-resistant Acinetobacter is a particular concern in hospitals and nursing homes, where contaminated surfaces or equipment can contribute to spread. Carbapenem-resistant Enterobacterales include strains of E. coli and Klebsiella, and the source report identifies patients using ventilators or catheters, as well as people on longer antibiotic courses, as more exposed to these infections. Drug-resistant gonorrhea can limit treatment options; the report says 55.4% of U.S. gonorrhea cases in 2023 were resistant to at least one of six antibiotics or had elevated minimum inhibitory concentrations.
The report also notes that the FDA approved gepotidacin and zoliflodacin in 2025 as new antibiotics for gonorrhea, described in the source report as the first new antibiotics for the infection in decades. Their approval does not remove the CDC’s concern about resistance or establish how well they will address the full range of resistant infections.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
Limits of the Report’s Estimates
The CDC’s combined estimate of 9.7 million infections and 50,800 deaths per year covers the report’s pathogens collectively. The supplied report summary does not provide the calculation details, a year-by-year trend for the combined total, or a breakdown of how much each of the 19 pathogens contributes to it. The figures should not be read as counts caused only by the four urgent drug-resistant pathogens.
The disease burden of several watch-list organisms is uncertain, according to the report. It is also not clear from the available material how the CDC will measure whether the new classifications or prevention efforts change infection and death totals in coming years. The C. auris case count and the hospitalization and death figures cited above refer to specific years and should not be treated as current-year totals.
Policy and Prevention Decisions
The report calls attention to infection prevention and the need for treatment options against resistant pathogens. Armstrong urged Congress to pass the PASTEUR Act, which would establish a federal program to support development of antimicrobial drugs aimed at high-priority pathogens and infections. According to the source report, versions of the bill remained stalled in congressional committees when the report was published.
Further developments include whether lawmakers advance the legislation and how health agencies, hospitals and researchers respond to the CDC’s updated classifications. The report’s watch-list organisms and pathogen-specific figures may also be monitored as new data become available. The provided material does not set out a date for a further CDC update.
Key Questions
Does the CDC say the four urgent pathogens cause 50,800 deaths each year?
No. The 50,800 annual deaths estimate applies to the pathogens covered by the report collectively. The four urgent drug-resistant pathogens are a subset, and the available summary does not give a combined annual death total for those four alone.
Which pathogens are in the CDC’s urgent category?
The report names Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae as urgent drug-resistant threats.
Why did C. difficile move to a lower threat category?
The CDC moved Clostridioides difficile from urgent to serious. The report attributes the change in part to infection-prevention measures that have helped reduce cases since 2011.
What does the CDC watch list mean?
The watch list includes organisms the CDC considers potential threats whose disease burden is uncertain. It is a monitoring category, not a claim that every listed organism is already causing widespread disease.
What is the PASTEUR Act?
As described in the report, the PASTEUR Act would create a federal program to support development of antimicrobial drugs for threatening pathogens and infections. Armstrong called for its passage; the source report said versions remained stalled in congressional committees.
Source: medpagetoday.com
